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Abstract In the screening of complex mixtures, for example
combinatorial libraries, natural extracts, and metabolic incu-
bations, different approaches are used for integrated bioaffin-
ity screening. Four major strategies can be used for screening
of bioactive mixtures for protein targets—pre-column and
post-column off-line, at-line, and on-line strategies. The focus
of this review is on recent developments in post-column on-
line screening, and the role of mass spectrometry (MS) in
these systems. On-line screening systems integrate separation
sciences, mass spectrometry, and biochemical methodology,
enabling screening for active compounds in complex mix-
tures. There are three main variants of on-line MS based
bioassays: the mass spectrometer is used for ligand identifi-
cation only; the mass spectrometer is used for both ligand
identification and bioassay readout; or MS detection is
conducted in parallel with at-line microfractionation with
off-line bioaffinity analysis. On the basis of the different fields
of application of on-line screening, the principles are
explained and their usefulness in the different fields of drug
research is critically evaluated. Furthermore, off-line screen-
ing is discussed briefly with the on-line and at-line
approaches.
Keywords Mass spectrometry . On-line based bioassays .
Post-column bioaffinity screening . Bioactive mixture
analysis
Abbreviations
Mant-
cGMP
2′-O-(N-methylanthraniloyl)guanosine-3′,5′-
cyclic monophosphate
AMC 7-Amido-4-methylcoumarin
AChE Acetylcholinesterase
AChBP Acetylcholine binding protein
ATP Adenosine triphosphate
APCI Atmospheric pressure chemical ionization
Z-FR CBZ–Phe–Arg
CYPs Cytochromes p450
cAMP Cyclic adenosine monophosphate
cGMP Cyclic guanosine monophosphate
ESI Electrospray ionization
ER Estrogen receptor
EIC Extracted-ion chromatogram
IT TOF Ion-trap–time-of-flight hybrid MS
GST Glutathione-S-transferase
HPLC High-performance liquid chromatography
HRS High-resolution screening
HTS High-throughput screening
MALDI Matrix-assisted laser-desorption ionization
MS Mass spectrometry
NMR Nuclear magnetic resonance spectroscopy
PKA Protein kinase A
SIM Selected-ion monitoring
SRM Selected-reaction monitoring
SPE Solid-phase extraction
Introduction
Within the pharmaceutical industry, microplate-based high-
throughput screening (HTS) methodology is used for most
bioaffinity screening applications from the early hit stage
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up to the phase of lead development. These approaches
suffer from a number of limitations, especially the purity of
the compounds screened. When dealing with mixtures,
identifying the individual bioactive compounds can be a
cumbersome endeavor. This is also true when combinatorial
chemistry and parallel synthetic libraries are used as
starting points for drug discovery.
Conventionally, when dealing with bioaffinity assess-
ment of mixtures, they are first fractionated [1], the
collected fractions are evaporated, and microplate bioassays
are used to detect the bioactive fractions, eventually in
parallel with compound identification by mass spectrometry
(MS) and/or nuclear magnetic resonance (NMR) spectros-
copy [2–7]. The general workflow of such a process is
depicted in Fig. 1. The challenge in these procedures lies in
the difficulty of correctly matching the dereplicated
bioactive compounds in particular fractions with their
chemical structure [8, 9]. Typical examples include frac-
tionation of intact proteins before matrix-assisted laser-
desorption ionization (MALDI) MS analysis [10], and
many types of biochemical assay formats that are con-
ducted after fractionation of bioactive mixtures, such as
natural extracts [11, 12], metabolic mixtures [13], and
environmental mixtures [14–17]. The main drawback is that
the high resolution obtained from the separation step
(chromatographic peaks of seconds to tens of seconds) is
often lost in the low-resolution fractionation process
(fractions in the minute range are common).
Recent advances in separation science and detection
technology have fuelled research into adjusted or newly
designed bioassay formats [18, 19]. Our research interest
is in bioassays hyphenated to analytical separation
techniques. Pre and on-column bioaffinity screening
formats will be reviewed by us in the near future [20];
this paper focuses on MS based post-column bioassay
formats.
The direct on-line post-column coupling of a bioassay to
a chromatographic separation is an effective alternative to
HTS. This so-called high-resolution screening (HRS)
demands rapid and straightforward on-line bioassays in
order to achieve high resolution and sensitivity [21–23].
HRS was pioneered by the research groups of Przyjazny
[24, 25] and Irth [26], using HRS systems based on UV or
fluorescence detection. In this review, the focus is on HRS
systems in which MS detection is an integrated part of the
analytical approach. There are currently three general ways
to implement MS detection in HRS:
1. MS detection replaces UVor fluorescence detection, thus
providing MS-based readout of the bioassay (Fig. 2a);
2. MS detection is performed in parallel with the
(fluorescence-based) on-line bioassay (Fig. 2b); and
3. MS detection is performed in parallel with micro-
fractionation before off-line bioassay (Fig. 2c).
In all three approaches, chemical information derived
from MS detection can be directly correlated with the
bioaffinity information [27–29]. Available examples of MS-
based HRS systems are reviewed and the merits and
limitations of the various approaches to MS-based HRS
bioassays are discussed.
On-line bioaffinity analysis with direct MS readout
History
Initial proof-of-principle of HRS approaches was performed
with colorimetric (UV–visible) and fluorescence readout. In
these studies, high-affinity binding partners, for example
biotin − (strept)avadin and/or digoxin − anti-digoxin anti-
bodies were used. The HPLC eluent with biotin and
biocytin as analytes was mixed with a continuous flow of
an avidin solution, in which a dye ligand with increased
absorption properties upon avidin binding provided the
detection principle [24]. Subsequently, UV detection was
replaced by fluorescence detection in a system in which
biotin, upon binding, results in fluorescence enhancement
of the fluorescently labeled avidin [25]. Although the
fluorescence-based bioassay was more sensitive, the tech-
nique was intrinsically compromised by the need for unknown
ligands to cause fluorescence enhancement upon binding. A
ligand displacement approach with a fluorescent antibody
tracer enabled analysis of unknown ligands by the use of an
immobilized ligand affinity column before detection [26].
Various other applications were developed along these lines.
Alternatives to the affinity trapping columns were also
Fig. 1 Traditional HTS with (often iterative) deconvolution processes:
(1) chromatographic separation, (2a and 2b) split to MS and a
fractionation device, (3) solvent evaporation step, (4) addition of
biochemical assay reagents, (5) incubation step, (6) assay readout with
a plate reader. Monitor screen, attempt to correlate low-resolution
bioaffinity trace with the high resolution MS trace
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investigated, e.g., the use of hollow fibers to separate tracer
ligand and antibodies [30], flow cytometry with analyte-
coated beads [31], and free-flow electrophoresis to separate
bound and unbound tracer analyte [32]. Theoretical concepts
of on-line post-column bioaffinity analysis were discussed in
detail by Oosterkamp et al. [33, 34].
MS for on-line bioassay readout
The first example of an on-line bioassay with electrospray
ionization (ESI) MS rather than fluorescence readout was
described by Hogenboom et al. [35]. A typical bioassay
setup with direct MS readout is depicted in Fig. 2a. The
competitive bioassay specifically used the high-affinity
streptavidin and fluorescein-biotin interaction. Because the
affinity interaction between biotin and streptavidin is one of
the strongest currently known interactions (Ka=0.6×10
15 L
mol−1), this affinity complex is easily preserved during the
ESI MS process. The use of fluorescein-biotin enabled
straightforward comparison with the fluorescence readout
demonstrated previously. A lower affinity interaction
between anti-digoxin and digoxin (Ka=approx. 10
9 L
mol−1) was also tested and gave comparable results. An
important consideration here is that in-solution dissociation
constants cannot simply be correlated with the degree of
conservation of non-covalent complexes in the gas phase.
Typically, complexes involving electrostatic interactions are
easily preserved or even strengthened because of the lack of
solvent shielding in a vacuum. In contrast, complexes
involving hydrophobic interaction tend to dissociate readily
in the gas phase. This implies that for every target–ligand
interaction, the optimum bioassay conditions for on-line
MS based bioassays have to be determined.
Derks et al. demonstrated one of the main advantages of
MS as readout, namely the ease of measuring different
ligand − target interactions simultaneously in one bioassay
Fig. 2 a. Schematic view of an on-line bioaffinity analysis or HRS
setup with MS based bioassay detection. (1) Separation (a gradient LC
system, an autoinjector, and a column are shown). The bioassay
comprises, first, the on-line addition of receptor via a superloop (2)
operated by an HPLC pump (3). Second, the tracer ligand is added in
a similar fashion by another HPLC pump (4) and superloop (5). The
first reaction coil (6) enables binding of eluting ligands followed by a
second incubation step in the second reaction coil (7) where the tracer
ligand is allowed to bind to the remaining free receptor binding sites
before detection by MS. Inset: schematic representation of the
biochemical binding process during on-line bioaffinity assay with
MS readout. b. Schematic view of a HRS setup with fluorescence-
based bioassay detection. (1) Separation with split to the on-line
bioassay and MS. Part of the bioassay operation is the same as
discussed for Fig. 2a (points 2 to 6). After on-line incubation of tracer
in the second reaction coil (7) detection occurs with a fluorescence
detector (FLD). Inset: Schematic representation of the biochemical
binding process during on-line bioaffinity assays. Shown is the
principle of fluorescence enhancement (for the AChBP). The assay
type can be converted into an MS-based bioassay by continuous
monitoring of the m/z of the (non-receptor bound) tracer ligand
(Fig. 2a). c. Principle of at-line bioaffinity analysis mode. After mixture
separation by gradient LC (1), one part of the column effluent is split to
MS for compound identification. The remaining part is directed towards
a mixing device (2) where it is mixed with all necessary biochemicals
via syringes (3 and 4). Subsequently, this mixture is micro fractionated
(5) and the so generated high-resolution well plate (384 or 1536 wells)
is incubated for any amount of time (6) before it is prepared to be read
on a plate reader (7) before eventual correlation with the MS trace
R
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[36]. They measured streptavidin − biotin and anti-digoxin
antibodies − digoxin interactions in one bioassay format.
The small ligand molecules (biotin and digoxin) were
chromatographically separated before on-line bioaffinity
analysis with direct MS readout.
When coupling the effluent of an LC separation on-line to a
bioassay, one has to be aware of specific compatibility
problems. First, the effluent has to be diluted to bioassay-
compatible conditions. Therefore, the organic modifier concen-
tration has to be lowered to a maximum of 5 to 10% for most
(soluble) enzyme and receptor targets. This means that dilution
by a factor of 10 to 20 has to be established, assuming that very
high organicmodifier concentrations are often used at the end of
reversed-phase gradients. Furthermore, as many LC separations
use acid modifiers, dilution (with bioassay buffer, target
enzyme, and tracer ligand or substrate) must also result in a
change in pH to a bioassay compatible pH. For this, the buffer
capacity should be sufficient; but for MS compatibility, on the
other hand, the buffer concentration should not be too high. For
the process of mixing in the post-column bioassay, a standard
inverted Y-piece suffices. The actual on-line incubation can
occur in normal PEEK tubing, but when slightly longer reaction
times are required (usually for enzymes), a knitted reaction coil
can be used instead to reduce post-column band broadening. A
typical advantage of this technique is that the very short post
column incubation times enable use of slightly higher concen-
trations of organic modifier than with traditional bioassays.
With potential ESI ion source contamination and the
associated ionization suppression in mind, one could raise
questions against the concept of direct ESI MS readout in
biochemical assays. Because of the continuous influx of
proteins, buffers, and, eventually, other constituents of the
bioassay into the ESI MS source, in several cases an on-line
bioassay is not truly compatible with ESI MS readout.
However, from the bioassay perspective, important benefits
are achieved with MS readout compared with fluorescence
readout. Most importantly, MS-based bioassays do not rely on
the availability of fluorescent probes, tracers, or substrates.
There are evident problems with fluorescent labeling because
ligands, substrates, or other bioassay components must be
chemically modified to incorporate the fluorescent label
required. With MS readout, native ligands or substrates can
be used. When, in addition, the bioassay is coupled on-line to
LC separation in a continuous-flow format for bioaffinity
assessment in mixtures, the MS can be used to
simultaneously measure drug target–ligand/substrate in-
teraction and identify the ligands/substrates [35]. For this
purpose, the mass spectrometer is used in two modes:
1. selected-ion monitoring (SIM) or selected-reaction
monitoring (SRM) to detect and quantify the free
ligand concentration (for ligand-binding assays) or the
product formed (for enzymatic drug targets); and
2. full-spectrum operation, eventually involving data-
dependent switching to MSn acquisition, to identify
the eluting ligands.
When looking in more detail at mass spectrometers that
could be used for full-spectrum operation (mode 2), the
advantages and disadvantages are the same as when
performing normal LC–MS(–MS) analysis. One has to bear
in mind, however, that when combining both bioassay
monitoring (mode 1) and analyte/ligand identification
(mode 2), the analyte/ligand identification part is hampered
by the post-column bioassay dilution and buffer conditions
that are less favorable for typically used positive ESI
ionization (low organic modifier concentration at a
bioassay-compatible pH of ~6 to 7.5). For the bioassay
part (mode 1), usually a robust and convenient mass
spectrometer should suffice (e.g. ion-trap or quadrupole)
but, because the analyte identification part (mode 2)
demands good sensitivity, resolution, and the possibility
of analyte fragmentation, often a hybrid mass spectrometer
is the first choice. When one deals with a bioassay with a
very low rate of enzymatic product formation or a low
concentration of enzyme in the bioassay, a triple-
quadrupole mass spectrometer, which enables very specific
and sensitive product monitoring, could be considered.
Until now however, in most cases a Q-TOF (or ion-trap–
time-of-flight) mass spectrometer has been the instrument
of choice enabling mode 1 with sufficient sensitivity and
specificity and mode 2 with sufficient sensitivity and
resolution and the possibility of analyte fragmentation.
Figure 3 shows a typical example of results obtained
with HRS methodology employing MS readout. In this
Fig. 3 Traces of an on-line bioassay for cathepsin B operated in flow-
injection analysis mode with MS as bioassay readout. An inhibitor is
injected in triplicate in increasing concentrations, shown in the bottom
MS trace, in order to identify eluting inhibitors. Bioaffinity is detected
as negative peaks by monitoring changes in the concentrations of both
resulting products AMC (middle AMC EIC trace) and Z-FR (upper Z-
FR EIC trace) from the enzymatic cleavage
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particular case, inhibition of the protease cathepsin B was
monitored (see below) [37]. Cathepsin B converts a
continuously introduced peptide substrate (Z–Phe–Arg–
AMC) into the two products Z–FR (CBZ–Phe–Arg) and
AMC (7-amido-4-methylcoumarin), which are monitored
by MS in SIM mode. Replicate injection of a concentration
series of an inhibitor results in negative peaks, the height of
which is related to the extent of protease inhibition. If the
inhibitor was an unknown compound, its MS and MSn
characteristics may have been retrieved from simulta-
neously acquired full-spectrum data also.
Next to the advantages, there are also some disadvantages
and limitations of MS-based bioassay readout [38], some of
which have already been discussed above. The disadvantages
primarily lie in the requirements needed for ESI MS analysis.
In general, (positive-ion) ESI MS is favored by a high organic
modifier content and low mobile phase pH, which is
incompatible with most bioassays. Second, ESI MS restricts
the type of buffers, buffer strength, and other additives present.
Generally, many non-volatile additives are used in bioassays to
mimic physiological conditions, e.g., phosphate buffers, non-
volatile salts such as sodium chloride, and co-factors. Blocking
agents and/or detergents are sometimes needed to prevent
adhesion of the target protein or protein complexes to the
surface of the reaction coils and HPLC tubing. All these
solvent constituents, necessary for good bioassay performance,
cause significant ionization suppression in ESI MS. In several
cases, the phosphate buffer in a bioassay can be easily replaced
by volatile and MS-compatible alternatives, for example
ammonium formate or ammonium acetate solutions (pH
between 6 and 7.5). However, in general, compromises in
solvent composition have to be made, and these, in turn,
compromise the performance of both the bioassay and the ESI
MS readout. Finally, the LC column effluents are diluted,
typically by a factor of 10 to 20, when mixed with the
biochemical reagents in the continuous-flow system for the
post-column incubation step before MS readout. Moreover,
band broadening occurs in the reaction coils during incubation.
Important aspects of getting an on-line MS-based bioassay
to function properly are, in most cases, the use of volatile
buffers at a slightly lower pH than 7 and a buffer strength that
just has the capacity to neutralize the often acidic LC effluent.
When cofactors and/or additional ions, e.g., magnesium,
sodium chloride, are needed, these also must be used in the
lowest possible concentration for the bioassay, which is often
much lower than those used with traditional bioassays. The
target enzyme or receptor is required in a (partly) purified
form. Finally, one must realize that the MS might have to be
cleaned somewhat more frequently than normally. Despite
these disadvantages and limitations, MS readout is still an
interesting option for HRS applications when no other
appropriate bioassay alternatives are available. Some addi-
tional application examples are discussed below.
Applications of on-line bioassays with MS readout
Acetylcholinesterase (AChE) is an enzyme that hydrolyzes
the neurotransmitter acetylcholine, producing choline and
acetic acid. AChE is found at neuromuscular junctions and
cholinergic synapses in the central nervous system, where
its activity serves to terminate synaptic transmission. As
such, AChE is the target of many Alzheimer's drugs, nerve
gases (e.g. Sarin), and insecticides.
An on-line bioassay with MS readout for the identi-
fication of AChE inhibitors was described by de Jong et
al. [39]. The native substrate acetylcholine was used and
the product choline was monitored on-line by MS readout.
Inhibitory compounds prevent product formation in the
reaction coils before MS. Figure 4 shows the MS traces of
both the substrate and the product in the on-line substrate
conversion assay, and the MS trace of the injected
inhibitor galantamine. It also shows the process of starting
up the bioassay in the first 20 min of the chromatograms.
The MS is operated in such a way that both inhibitor
Fig. 4 On-line monitoring of AChE-catalyzed hydrolysis of the
native substrate acetylcholine (ACh, lower trace) into its product
choline (Ch, middle trace). The bioassay start-up events are also
shown. After ~5 min (1), ACh is continuously added, resulting in an
increased baseline for the EIC trace of the m/z corresponding to ACh.
Subsequent start-up of continuous addition of the enzyme AChE at
~15 min (2) starts the on-line enzymatic conversion detected as a
reduced EIC trace of the m/z of ACh and an increased EIC trace the m/
z of the product Ch. The upper trace shows the injected inhibitor
galanthamine identified in the MS trace by its molecular mass.
Inhibitory peaks are consequently detected in the lower two bioaffinity
traces as negative peaks for Ch and positive peaks for ACh. (Adapted
from de Jong et al. [39])
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identification and on-line enzyme activity monitoring are
achieved.
Phosphorylation and de-phosphorylation of proteins and
peptides, and the formation and breakdown of cyclic
phosphate molecules, e.g., cAMP and cGMP, are pivotal
for most endogenous signaling processes [40]. Protein
phosphatase and kinase enzymes are involved in these
processes. Post-column on-line affinity-based analysis of
phosphorylated peptides and proteins was described by
Krabbe et al. [41, 42], who used a ligand-exchange reaction
between eluting phosphopeptides/proteins and the metal–
ligand complex iron(III)–methylcalcein blue, which
releases the tracer ligand methylcalcein blue. The reaction
is monitored by MS, switching between SIM and data-
dependent MS–MS, enabling both quantification of the
tracer and identification of the phosphopeptides. This
proof-of-principle study also demonstrated that the ap-
proach, although elegant, lacks sufficient sensitivity for
studies in which very low concentrations of phosphopep-
tides are involved, for example phosphoproteomics studies.
Different approaches to an on-line inhibition assay of a
protease/peptidase were reported by de Boer et al. [37, 43,
44], who used the enzymatic conversion of a peptide
substrate by cathepsin B into two products (Z-FR and
AMC) as a model system. Product formation was contin-
uously monitored by direct on-line ESI MS (Fig. 3). The
enzymatic conversion rate was reduced on injection of an
inhibitor, resulting in negative peaks in the MS readout. By
combining SIM analysis of the products and full-spectrum
analysis, unknown inhibitors can be detected and charac-
terized, using the extracted-ion chromatogram (EIC), as
shown in Fig. 5, where a fungal extract containing bioactive
compounds is profiled. Correlation between SIM and EIC
traces enables retention time and peak shape correlation
between bioaffinity and chemical information (m/z of the
inhibitor) [37]. In a follow-up study, high-temperature
LC, enabling lower organic modifier concentrations, was
demonstrated [43]. As the ESI MS source in direct
monitoring of a biochemical reaction mixture is prone to
contamination, miniaturization of the bioassay can be
highly advantageous. Reduction of the flow-rate of the
bioassay to the ESI MS source by a factor of 25–50 was
achieved by use of microfluidics-based continuous flow
[44].
Fig. 5 HRS analysis of a fungal extract for Cathepsin B inhibitors.
(a) Extracted ion chromatogram (EIC) of the enzymatic cleavage
product AMC (m/z 176.0). (b) EIC of the other enzymatic cleavage
product Z-FR (m/z 456.0). (c−g) EIC of various m/z values, which
were present as an abundant peak in the mass spectrum recorded at
tR=43.3 min. c EIC of m/z 211.0. (d) EIC of m/z 230.0. (e) EIC of m/
z 292.9. The EICs of m/z 677.3 (f) and of m/z 693.2 (g) have peaks
with the same retention time and peak shape as the bioactive peaks,
thus correlating bioaffinity with identity (in terms of m/z values
measured; adapted from de Boer et al. [37])
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On-line bioaffinity analysis with parallel MS detection
As discussed above, direct MS readout of bioassays is not
always attractive, especially because of potential ioniza-
tion suppression effects. However, it must be emphasized
that on-line implementation of MS detection in HRS
applications is necessary for compound identification. In
that case, on-line MS detection is performed in parallel
with the bioassay readout based on, e.g., fluorescence
detection. This general setup is depicted in Fig. 2b. It
features a post-column split with part of the column
effluent being directed to the continuous-flow bioassay
and another part to ESI MS (or MSn) for simultaneous
chemical characterization of the eluting bioactive com-
pounds. The parallel setup enables direct correlation of
chemical and biological information (in a similar way as
demonstrated for direct MS readout in Fig. 5). For analysis
of bioactive mixtures, this setup is a powerful and
versatile alternative to traditional fractionation processes
followed by microplate bioassays.
In this section, various examples and applications of
on-line bioaffinity analysis with parallel MS detection are
reviewed. In this HRS format, ligand-binding and
substrate conversion bioassays are most conveniently
incorporated. For this, fast and straightforward bioassays
are needed in order to allow sensitive detection and
limited post-column band broadening in the reaction
coils. However, a good percentage of targets with
corresponding biochemical assay formats can be imple-
mented efficiently in HRS systems. Examples include
nuclear receptors, protein kinases, proteases, phospho-
diesterases and phosphatases, and metabolic enzymes. In
these cases, HRS can often give very rapid, robust and
complete bioaffinity profiles of mixtures containing
bioactive compounds.
Enzymatic conversion by AChE and binding to AChBP
Before the development of the MS-based on-line AChE
bioassay, another, colorimetry-based, on-line bioassay
was used [45] to enable the identification of inhibitors in
extracts of the narcissus “Sir Winston Churchill” [46]. The
alkaloid ungiminorine was found to have a mild inhibitory
effect on AChE. A more sensitive AChE bioassay was
achieved by the use of a substrate which is hydrolyzed to a
highly fluorescent product [47]. Using this approach,
various bioactive plant extracts from bulbs of Galanthus
nivalis, Eucharis amazonica, Crinum powelli, and Nerine
bowdenii were screened and compounds with strong
AChE inhibitory activity were detected and characterized
by parallel MS detection. The same HRS system was used
by Marques et al. to screen microsomal metabolic
incubations of the first-generation Alzheimer’s drug
tacrine for bioactive metabolites [48]. Parallel MS and
off-line NMR after fraction collection was performed to
characterize the metabolites. This example demonstrates
that in some cases MS and MSn characterization is
insufficient for full identification of unknown bioactive
compounds. The correlation between bioaffinity and MS-
based chemical information obtained from HRS may
direct fractionation. This improves the efficiency of
purification and further structure elucidation, e.g., by
NMR (see below).
Recently, an on-line bioaffinity screening approach
related to the acetylcholine binding protein (AChBP) was
described [49]. AChBP is a relevant model protein for the
family of nicotinic acetylcholine receptors, important
receptors possibly involved in many brain-related diseases,
for example Alzheimer’s and Parkinson’s disease, ADHD
(attention deficit/hyperactivity disorder) and chronic pain-
related disorders. The bioaffinity detection is based on a
specially developed tracer ligand the fluorescence of which
is enhanced in the binding pocket of the protein. A
schematic representation of the on-line bioassay principle
is given as inset in Fig. 2b. Parallel MS detection was
performed next to a parallel dual bioassay, one to assess the
bioaffinity of the eluting ligands and the other a “blank”
bioassay performed to detect native fluorescence properties
of eluting compounds. The objective of the bioassay was
analysis of small focused medicinal chemistry-like libraries
and it enabled estimation of pKi values of known
compounds after injection at only one concentration, even
for ligands in a mixture [49].
Bioassays with soluble receptors
HRS screening of mixtures for receptor affinity can be
performed in different bioassay setups. For instance, a
fluorescently labeled receptor can be used in conjunction
with an immobilized affinity column at the end of the
reaction coil, as used in antigen–antibody interactions (see
above) [26] and in the screening of ligand mixtures for the
urokinase receptor [50].
Alternatively, a homogeneous continuous-flow bioassay
(without filtration or affinity column separation steps) can
be used, as, for instance, demonstrated for estrogen receptor
binding. In this case, fluorescence enhancement with the
natural fluorescent estrogenic tracer ligand coumestrol is
monitored [51]. Eluting ligands that displace coumestrol
provide negative peaks on the baseline. Eventually, espe-
cially to increase sensitivity, a restricted access column can
be used at the end of the reaction coils to remove the
fluorescent non-receptor-bound coumestrol fraction from
the solvent stream. As an alternative to fluorescence
enhancement, detection based on fluorescence polarization
(FP) has also been reported [52].
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In an MS-based HRS setup, an estrogen receptor (ER)
bioassay is especially interesting in the analysis of natural
compounds such as phytoestrogens [27, 53], environmental
samples, screening for endocrine-disrupting compounds
[54] and metabolic mixtures, and profiling bioactive drug
metabolites [55–57].
Various parts of the pomegranate fruit (Punica gran-
atum; Punicaceae), e.g., juice, seed oil, and peel extract,
have been shown to exert suppressive effects on human
breast cancer cells in-vitro. A crude mixture of pomegran-
ate peel extract was separated by HPLC followed by on-
line bioaffinity analysis for the ER-β with parallel MS and
MS–MS detection [53]. Three estrogenic compounds
(luteolin, kaempferol, and quercetin) were detected and
identified by comparing the molecular masses and
negative-ion atmospheric-pressure chemical ionization
(APCI) MS–MS spectra with data from an estrogenic
compound library.
In order to efficiently assess the contribution of drug
metabolites to the overall therapeutic and adverse effects,
profiling of bioactive metabolites in metabolic mixtures is
important in drug discovery. The power of HRS in this area
was first demonstrated for metabolites of the nonsteroidal
antiestrogen tamoxifen, used in the hormonal therapy of
human breast cancer and, moreover, as a chemopreventive
agent for women with an enhanced risk of developing
breast cancer. Tamoxifen is known to be metabolized into
multiple mono and dihydroxylated and N-demethylated
derivatives, some of which have a much higher bioaffinity
than tamoxifen itself. Metabolites in metabolic mixtures of
tamoxifen were identified with simultaneous bioaffinity
profiles for the ER-α [55]. For production of metabolic
mixtures, incubations with microsomal liver fractions
containing the most important cytochrome P450 isoen-
zymes involved in phase I metabolism are usually
conducted. The results found were in accordance with
many separate studies from the past, based on conven-
tional screening directed at the bioaffinity of specific
metabolites only. Subsequently, the HRS system was
combined with parallel at-line bioreactors that enabled
simultaneous metabolic CYP incubations of antiestro-
genic drugs followed by on-line solid-phase extraction
(SPE) trapping, washing, and elution to the HRS part of
the system [54, 56]. As a result, metabolic schemes could
be constructed, including bioaffinity information per
metabolite.
Metabolic profiling with MS and MS–MS detection
often does not lead to complete structure elucidation of
the metabolites. HRS was therefore incorporated in a
wider approach capable of efficiently profiling metab-
olites for their individual bioaffinity in combination
with total structure elucidation by high resolution MS
with an ion-trap–time-of-flight hybrid MS (IT-TOF),
fractionation by preparative LC, and off-line NMR
spectroscopy [57]. Dual parallel bioassays for ER-α and
ER-β were included in the approach. Metabolites of
known estrogenic drugs were generated using conven-
tional CYP incubation (with human liver microsomes)
and genetically engineered BM3 mutants (mutants of
bacterial CYPs) [58, 59]. A typical HRS result obtained
by use of this system is shown in Fig. 6. Bioactivity
chromatograms from the parallel (dual) ER-α/ER-β bio-
assays are shown for metabolic mixtures (from human
liver microsomes) of α-estradiol and β-estradiol injected
at two concentrations. Finally, the bottom chromatograms
show EIC traces from parallel MS detection of the
mixture of α-estradiol metabolites.
Bioassays for phosphate-related ligands or substrates
As already indicated, phosphorylation and de-phosphorylation
processes, and formation and breakdown of cyclic phosphate
molecules (e.g. cAMP and cGMP) are pivotal for most
endogenous signaling processes [40].
An HRS system for detection of phosphodiesterase
(PDE) inhibitors in natural extracts, based on the conver-
sion of the fluorescent substrate Mant-cGMP (2′-O-(N-
methylanthraniloyl)guanosine-3′,5′-cyclic monophosphate)
into the highly fluorescent Mant-GMP was developed by
Schenk at al. [22]. The applicability of the system was
shown by analyzing a plant extract spiked with two PDE
inhibitors. Quantification of the active compounds was by
evaporative light-scattering detection, thus enabling estima-
tion of the IC50 values of the bioactive compounds directly
from the crude extract.
A generic on-line bioassay for phosphate-consuming or
releasing enzymes was developed and applied to measure-
ment of continuous phosphate release from alkaline
phosphatase and to detection of tetramisole in a plant
extract as an inhibitor of the enzyme [60]. A fluorophore-
labeled phosphate-binding protein with strong fluorescence
enhancement on binding to inorganic phosphate was used
for readout, and parallel MS for confirmation of identity of
the inhibitor.
In the vast majority of signaling pathways, protein
kinases play pivotal roles in transmitting ligand-mediated
signals by (de)phosphorylating proteins. Therefore, protein
kinases are important targets for inhibition screening. The
MAP kinase p38α (p38) is important in some types of
cancer and inflammation processes and is regarded as a
(potential) drug target. The development of an HRS system
based on fluorescence enhancement in the (ATP) binding
pocket of protein kinase p38 was demonstrated by Falck et
al. [61]. Parallel MS enabled efficient correlation between
bioaffinity for p38 kinase and identity of the inhibitor
compounds.
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Bioassays for proteases and peptidases
Proteases (and peptidases) are important in many biological
processes, for example different hormonal processes in
which cleavage of peptides or proteins changes the
bioaffinity of proteins involved, in protein homeostasis of
the body, and in many physiological reactions, from food
digestion to blood-clotting and apoptosis. Various HRS
approaches to assay protease activity or inhibition have
been reported. In addition to the systems with direct MS
readout, already discussed, systems with parallel MS have
also been reported.
The angiotensin-converting enzyme (ACE) is an exo-
peptidase that is important in blood pressure regulation. An
HRS system with parallel MS was developed for screening
of ACE inhibitors [62]. Accurate-mass data, MS–MS
fingerprints, and protein database search procedures were
used to identify bioactive peptides found in mixtures, such
as hydrolyzed milk samples, digests, or fermentation
products.
Fig. 6 As metabolism of drugs can result in the formation of
pharmacologically active metabolites, it renders them essential for early
consideration in drug discovery and development programs. The figure
shows HRS analysis used to rapidly enable the identification of
individual estrogenic ligands in metabolic mixtures with simultaneous
detection of their biological activity. Shown are analyses of metabolic
mixtures, injected at two different concentrations depicted as super-
imposed solid and dotted bioaffinity chromatograms, of α-estradiol and
β-estradiol. Parallel analysis of bioaffinity towards two ER subtypes
(α and β) gives selectivity information. The m/z traces of expected
and unexpected metabolites are plotted at the bottom of the figure to
enable retention time and peak shape correlation in order to correlate
bioactivities with identities. The m/z traces of the mother compounds
are not shown. The second-last bioactive peak is from α-estradiol
and the last one (longest retention time) is from β-estradiol.
Metabolism was from human liver microsomes
Mass spectrometry-based post-column bioaffinity profiling 2663
HRS screening for inhibitors of serine proteases, based
on a fluorescently labeled peptide tracer that yields
increased fluorescence on cleavage was recently demon-
strated [63]. In order to keep the modifier concentration in
the bioassay constant during gradient elution, a counter
gradient was used that was parked in a semi-preparative LC
column.
For analysis of the proteolytic enzyme activity of
individual proteases in mixtures, the on-line combination
of size-exclusion LC and ion-exchange chromatography
under non-denaturing conditions and a bioassay has been
developed by Schebb et al. [64]. Bioassay readout by UV
detection is based on the protease cleavage of a p-nitroani-
line-labeled peptide, releasing the colored p-nitroaniline.
The method was applied to the characterization of the crude
venom of the pit viper Bothrops moojeni and extracts of the
pathogenic amoeba Acanthamoeba castellanii. It is a tool
for serine protease screening in general by fast ESI MS–MS
identification of active samples followed by the separation
and isolation of active sample constituents in on-line
bioaffinity analysis mode.
Off-line and at-line bioaffinity analysis with parallel MS
detection
Although a great variety of bioassays can be converted into
HRS systems with parallel MS detection, HRS is not
always feasible, for instance because of the bioassay
conditions demanded. It is difficult, or impossible, to use
the HRS approach for bioassays requiring poorly soluble
constituents, membrane-bound targets, and/or very long
incubation times. Although use of gas-segmented post-
column systems to reduce post-column band broadening
effects has been demonstrated [65], such an approach
provides only a very limited extension of the incubation
time. Also, cellular bioassays [66–68] are currently out of
reach. Targets present at very low concentrations and targets
that require indirect means of detection are cumbersome to
analyze with HRS methods. In such cases, the use of off-line
or at-line techniques, which are still capable of correlating
bioaffinity/bioactivity and chemical information on bioactive
compounds in a mixture, can be considered [29]. Some
examples are reviewed in the next section.
Off-line bioaffinity analysis
In the conventional approach to bioaffinity or bioactivity
screening, which involves fractionation of the column
effluent and subsequent plate reader-based bioassays, often
using fluorescence readouts [69], MS is increasingly
recognized as a universal, label-free tool for monitoring
enzymatic reactions [70, 71], or determining the affinity of
small molecules for a target protein [72]. MS is, therefore,
increasingly being used for off-line screening of small
molecules. A fully integrated platform with online sample
cleanup, capable of sampling rates as fast as ~5–10 s per
sample, is the so-called “RapidFire” technology [73–75].
The method involves rapid SPE purifications from assays
conducted in 96 or 384-well plates after incubation.
Extracted substrate(s) and/or product(s) from the incuba-
tions are rapidly eluted from the SPE cartridge into a triple-
quadrupole mass spectrometer in order to quantify the
substrate and product [76]. Figure 7 shows a schematic
overview of the technology in combination with some
typical results from a well plate analyzed. Bioassays for the
screening of CYP inhibition [77], antibacterial substances
[78], and others [79, 80] have been reported. The
advantages of such an approach are the possibility of
measuring not only one formed product, or converted
substrate, but basically both, or even multiple products in a
label-free manner. Until now, the technology has only been
applied to pure compound screening.
A more-or-less generic approach for protein kinase
screening involves use of a Caliper microfluidics platform
based on parallel capillary electrophoretic separations and
detection by laser-induced fluorescence [81–84]. In theory,
the microfluidics platform could be placed on-line with MS,
enabling label-free screening.
Another interesting off-line screening approach is based
on the MALDI Flash Quant technology, basically a MALDI
triple-quadrupole system operated in SRM mode to
overcome interferences from the MALDI matrix [85, 86].
This technology has been used to determine the binding of
small molecules to the murine GABA (gamma-amino-
Fig. 7 Left. Schematic view of a RapidFire system. Only a microtiter
well plate, the switch valves used for the rapid SPE steps, and a mass
spectrometer are shown. Right. Typical results shown for five of the
(96 or 384) wells analyzed. In well C6, an inhibitor prevented product
formation, which is shown as a lower product peak (SRM trace of
product m/z) and a higher substrate peak (SRM trace of substrate m/z)
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butyric acid) receptor mGAT 1 [87], to determine the
inhibition of protein kinase A (PKA) [88], and, in a
multiplexed system, to investigate the enzyme activity of
a kinase and an esterase in a single analysis [89].
At-line bioaffinity analysis
At-line bioaffinity screening combines the traditional
fractionation approach with on-line bioaffinity analysis
[29]. This technique involves mixing of the necessary
biochemicals with the column effluent just before the
fractionation process (Fig. 2c) and microfractionation, that
is fractionation in a seconds rather than minutes time frame,
to retain the high-resolution chromatographic separation.
This enables correlation of the bioaffinity data with the
chemical data from the MS which is positioned parallel to
the microfractionator. As the bioassay is performed
virtually off-line in 384 or 1536-well plates, free choices
in incubation time, necessary biochemical additives, and
readout formats can be made, because separation and
incubation are independent. Moreover, drying and mixing
issues are circumvented as the microtiter plates already
contain the homogenous bioassay mixture with the
fractionated compounds ready for incubation before plate
reader-based bioaffinity analysis. Additional post-column
splits in both on-line and at-line approaches can be used
to run several biochemical assays in parallel. At-line
bioaffinity screening has so far been demonstrated for
screening of PKA inhibitors [29] and antibacterial
substances [90]. In both cases, reconstructed high-
resolution bioaffinity chromatograms could be plotted
and compared with the MS chromatograms for
bioaffinity-to-identity correlation. In the latter case, a
regio-isomeric mixture of N-alkylated neomycin deriva-
tives was separated, mixed with bacterial inoculum,
incubated for 18 h, and, after addition of readout reagent,
the antibacterial effect of the eluting substances was
determined. Elucidation of the structures of the different
(bioactive) regio-isomers could be accomplished by MSn
analysis on an IT-TOF MS instrument.
Conclusions and perspectives
A wide variety of bioassay formats for different biological
targets and assay types have been successfully transformed
into on-line or at-line bioassays with direct coupling to
separation for mixture analysis. Additional bioassay for-
mats involve pre-column and on-column techniques.
Although all these hyphenated screening approaches can
rapidly deliver comprehensive bioaffinity information with
correlated compound identities, one must remember that
after identification of the bioactive compounds found,
traditional approaches have to take over. The hyphenated
screening approaches are not suited to subsequent purifica-
tion and/or synthesis of the bioactive compounds. There are
three other main reasons why traditional approaches must
be used after HRS-based identification of bioactive com-
pounds in mixtures. First, most research facilities are
adapted to traditional and integrated workflows of analyz-
ing pure compounds from the hit stage to the lead
development phase. Second, advances in more traditional
screening now even enable elaborate and comprehensive
“high content” analysis of single compounds that hyphen-
ated bioassay-analytical screening methods can not yet
compete with. Third, traditional techniques are applicable
to a wider range of assays, from easy ligand-binding
bioassays to high-content cellular biological assays with
multiple readouts. Nevertheless, as a first and important
step in finding and identifying bioactive compounds, HRS
and related techniques discussed in this paper can play an
important role, especially in the dereplication of bioactive
mixtures. When an HRS strategy has been developed,
bioactive mixture profiling can be performed more
rapidly and in a more convenient fashion. Drug target
classes that are most conveniently incorporated in on-line
screening processes are, for instance, nuclear receptors,
protein kinases, proteases, phosphodiesterases, phospha-
tases, and metabolic enzymes. Enzymes that are able to
rapidly convert substrates into fluorescent products and
receptors for which ligands are available that show
fluorescence enhancement in the binding pocket are most
suitable in this regard. For other enzyme and receptor
drug targets, on-line MS-based bioassays or at-line
screening methods are good alternatives, e.g., for
bioassay formats for which only native substrates or
ligands are available, bioassays that demand long
incubation times, and other difficult bioassay formats,
for example those involving membrane-bound drug
targets and cellular assay formats. Although it is difficult
to directly incorporate on-line and at-line approaches in
traditional drug-discovery processes, efficient incorpora-
tion is certainly possible with modifications.
In summary, on-line and at-line strategies used to profile
bioactive mixtures provide powerful tools for mixture
analysis, capable of rapidly and straightforwardly correlat-
ing bioaffinity with compound identity. They do, however,
need some development time and effort per drug target to
be screened for and flexibility in terms of implementation
into traditional drug-discovery workflows.
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